10-K: Alignment Health Soars: Net Loss Narrows, EBITDA Jumps 8111%

Alignment Healthcare reports significant revenue and membership growth, dramatically reducing net loss and boosting Adjusted EBITDA in its 2025 annual filing.

Summary

• Health Plan Membership grew by 25.0% to 236,300 members as of December 31, 2025, representing a 30% compound annual growth rate since inception.
• Total revenues increased by 46.1% to $3,948.7 million for the year ended December 31, 2025, up from $2,703.6 million in 2024.
• Net loss significantly decreased to $(978) thousand in 2025, a substantial improvement from $(128,071) thousand in 2024.
• Adjusted EBITDA saw an exponential increase to $109,944 thousand in 2025, compared to $1,339 thousand in 2024.
• Adjusted Gross Profit rose by 63.5% to $494,775 thousand in 2025 from $302,607 thousand in 2024.
• The Medical Benefits Ratio (MBR) improved to 87.5% in 2025 from 88.8% in 2024, indicating better cost management.
• 100% of members are enrolled in plans with a 4.0 Star rating or greater for the 2026 rating year, qualifying for increased premium payments.
• The company refinanced its debt in November 2024, issuing $330.0 million of 4.25% Convertible Senior Notes due November 15, 2029, replacing higher-interest term loans.
• A new $200.0 million senior secured revolving credit facility was entered into on February 26, 2026, maturing on February 26, 2029.
• Participation in the CMS ACO REACH model was discontinued as of December 31, 2025, with an expected immaterial impact on financial results.
• The company operates in 45 markets across California, North Carolina, Nevada, Arizona, and Texas, serving approximately 8.4 million Medicare-eligible seniors.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, marked by significant revenue and membership growth, a substantial reduction in net loss, and a dramatic increase in Adjusted EBITDA. The company's high CMS Star Ratings and strategic investments in its technology platform and care model position it well for future growth, despite ongoing regulatory complexities and competitive pressures.

Positives

• Total revenues increased by 46.1% to $3,948.7 million in 2025, demonstrating strong top-line growth.
• Health Plan Membership grew by 25.0% to 236,300 members, indicating successful member acquisition and retention strategies.
• Net loss was dramatically reduced from $128.1 million in 2024 to $1.0 million in 2025, nearing profitability.
• Adjusted EBITDA surged from $1.3 million in 2024 to $109.9 million in 2025, reflecting improved operational efficiency and scalability.
• The Medical Benefits Ratio (MBR) improved to 87.5% in 2025 from 88.8% in 2024, suggesting effective medical cost management.
• All health plan members are enrolled in plans with a 4.0 Star rating or greater for the 2026 rating year, which provides additional economic incentives from CMS.
• Debt refinancing in November 2024 replaced term loans with an average interest rate of 11.77% with 4.25% Convertible Senior Notes, reducing interest expense by $7.7 million in 2025.
• Selling, general, and administrative expenses decreased as a percentage of revenue in 2025 compared to 2024, indicating economies of scale from membership growth.
• Cash and cash equivalents increased to $575.8 million as of December 31, 2025, from $432.9 million in 2024, strengthening liquidity.

Negatives

• The company still reported a net loss of $0.978 million in 2025, indicating it has not yet achieved sustained profitability.
• Medical expenses increased by $1,053.3 million in 2025, driven by membership growth, higher unit costs, and increased Part D cost sharing due to the Inflation Reduction Act.
• Selling, general, and administrative expenses increased by $72.0 million in absolute terms in 2025, reflecting ongoing investments in growth.
• The company's business is highly dependent on government-subsidized Medicare Advantage programs, exposing it to risks from changes in funding and regulations.
• Uncertainty surrounds the application and potential financial impact of CMS's Risk-Adjustment Data Validation (RADV) audits, especially after a federal court vacated the 2023 final rule on extrapolation.
• The Inflation Reduction Act (IRA) changes to the Medicare Part D program are expected to increase the company's financial responsibility for prescription drug costs and administrative burdens.
• Membership is concentrated in a limited number of U.S. states, with approximately 84% in California, increasing exposure to regional economic, health, or regulatory conditions.
• The healthcare industry is highly competitive, with many competitors having larger membership bases and greater financial resources.

Risks

• History of net losses and ability to achieve or maintain profitability in an environment of increasing expenses.
• Viability of growth strategy and ability to realize expected results.
• Ability to attract new members and successfully enter new markets.
• Quality and pricing of products and services; ability to develop new products and implement clinical initiatives, lower costs, and appropriately document members' risk profiles; adequacy of benefits expense estimates.
• Ability to maintain or improve Star ratings in future years, which may have a direct and substantial adverse impact on revenue.
• Ability to develop and maintain satisfactory relationships with care providers.
• Risks associated with being a government contractor, including potential loss of CMS contracts, suspension from Medicare Advantage, changes to premiums, risk sharing, and governmental audits/investigations.
• Impact of cybersecurity breaches, loss of data, or other disruptions causing compromise of sensitive information or preventing access to critical information.
• Impact of disruptions in disaster recovery systems or management continuity planning.
• Dependence on reimbursements by CMS and premium payments by individuals.
• Impact on business if the healthcare services industry becomes more cyclical.
• Ability to manage acquisitions, divestitures, and other significant transactions successfully.
• Ability to maintain, enhance, and protect reputation and brand recognition.
• Ability to effectively invest in, implement improvements to, and properly maintain the uninterrupted operation and data integrity of information technology and other business systems.
• Ability to obtain, maintain, protect, and enforce intellectual property protection for technology.
• Impact of any restrictions on use of or ability to license data or failure to license data and integrate third-party technologies.
• Cost and other potential adverse impacts of legal proceedings and litigation, including intellectual property and privacy disputes.
• Dependence on senior management team and other key employees.
• Concentration of health plans in a limited number of U.S. states.
• Ability to generate sufficient cash flow to service all indebtedness and potential impact of covenants in credit agreement.
• Impact of shortages of qualified personnel and related increases in labor costs.
• Risk that records may contain inaccurate or unsupportable information regarding risk adjustment scores of members.
• Ability to accurately estimate incurred but not reported medical expenses.
• Impact of negative publicity regarding the managed healthcare industry.
• Impact of weather and other factors beyond control on clinics, external provider centers, and AVA platform facilities.
• Impact on business of renegotiation, non-renewal, or termination of risk agreements with providers.
• Risks associated with estimating the amount of liabilities recognized under risk agreements with providers.
• Ability to respond to general economic conditions, including increased inflation and higher interest rates.
• Risks associated with an economic downturn, including pressure on governmental budgets and reduced spending for health and human service programs.
• Ability to develop and maintain proper and effective internal control over financial reporting.
• Impact of state and federal efforts to reduce Medicare spending.
• Ability to comply with applicable federal, state, and local rules and regulations, including those relating to data privacy and security.
• Risks related to the use of machine learning and artificial intelligence, including within the AVA platform, which may introduce operational, regulatory, and legal risks.
• Risks associated with delegating services and functions to vendors, including supplemental benefit providers and third-party brokers.
• Risks related to new laws or changes in laws or their application increasing the cost of doing business.
• Risks related to adapting to changes in the healthcare industry and related regulations.
• Risks of losing services of licensed physicians who own associated physician practices.
• Risks related to existing indebtedness and growth prospects, particularly in an environment of rising interest rates.
• Failure to raise additional capital or generate cash flows could reduce ability to compete successfully.
• Requirements of being a public company may strain resources and distract management.
• Provisions of corporate governance documents could make an acquisition more difficult.
• Exclusive forum provision in certificate of incorporation may discourage lawsuits against directors and officers.
• An active, liquid trading market for common stock may not be sustained.
• Operating results and stock price may be volatile.
• Future sales of substantial amounts of common stock, or the possibility of such sales, could adversely affect stock price.
• Conversion of convertible notes may dilute percentage of ownership and negatively impact trading prices.
• Outstanding convertible notes may impact trading price of common stock.
• If securities or industry analysts do not publish research or reports, or if recommendations change, stock price and trading volume could decline.
• Issuance of preferred stock in the future could make acquisition difficult or adversely affect common stockholders.
• No current plans to pay regular cash dividends.
• Economic downturn or unstable market conditions, including rising inflation, may have adverse consequences.
• Corporate culture may be difficult to maintain as the company grows.
• Third parties may initiate legal proceedings alleging intellectual property infringement.

Future Outlook

The company anticipates substantial increases in aggregate costs due to planned investments in expanding its member base, provider networks, geographic reach, marketing, and technology, as well as public company operating expenses. It expects higher per-member medical costs in the first and fourth quarters due to seasonal illnesses and continued increases in corporate, general, and administrative expenses. While liquid assets are projected to be sufficient for operating and organic capital needs for at least the next 12 months, additional capital may be required for strategic initiatives and acquisitions. Regulatory changes, such as CMS's proposed 2027 Star Ratings adjustments and the Inflation Reduction Act's impact on Part D, could negatively affect future financial performance and increase compliance costs. The finalization of HIPAA security standards in May 2026 and new CPPA regulations also introduce significant compliance obligations. CMS's expanded RADV audit program, despite recent legal uncertainty, poses a continuous risk of payment recoveries.

Management Comments

• "Our Mission: Improve Healthcare, One Senior at a Time."
• "We aim to bring this senior-first healthcare experience to millions in the United States, become the most trusted senior healthcare brand in the country, and ultimately do well by doing good."
• "We believe our plans are differentiated because of our unique ability to manage costs by delivering proactive care and manage chronic conditions through an integrated clinical and technology model."
• "We approach Medicare Advantage as a care management business."
• "We focus on providing more care, not less, to our chronic and high-risk members to achieve superior results."
• "Our virtuous cycle, based on the principle of doing well by doing good, is highly repeatable and a core tenet of our ability to continue to expand in existing and new markets in the future."
• "We anticipate continuing to invest heavily in our growth efforts in the near future, which we believe will be an important driver of long-term value creation."
• "We believe that our liquid assets will be sufficient to fund our operating and organic capital needs for at least the next 12 months."
• The Board, with input from the Compensation Committee and its independent compensation consultant, considered the importance of retaining Mr. Kao, a recognized industry leader, while incentivizing long-term, sustained business performance and alignment with stockholder interests.

Industry Context

StockSavvy.ai notes that Alignment Healthcare operates in the highly competitive U.S. healthcare insurance industry, specifically targeting the Medicare Advantage market. The company's emphasis on a "senior-first" approach, integrated clinical and technology model (AVA platform), and proactive care management aligns with broader industry trends focusing on value-based care, chronic condition management, and enhanced member experience. The significant growth in Health Plan Membership and revenue, coupled with improved MBR, suggests effective execution within this competitive landscape. However, the industry remains heavily regulated by CMS, with ongoing changes (e.g., Inflation Reduction Act, RADV audits, HIPAA security standards) posing continuous compliance and financial risks. The company's strategy to reinvest cost savings into richer benefits and expand into new markets is a common competitive tactic to attract and retain members in a market where Star Ratings and price are significant factors.

Comparison to Industry Standards

• 100% of our health plan members are enrolled in plans rated 4 stars and above, meaning our members consistently receive a high-quality care experience, as defined under CMS star measurement criteria. The California HMO plan has achieved a 4 star or greater rating for nine consecutive years, indicating sustained high performance.
• For the 2026 Star ratings, only 18 MA-Part D contracts earned a 5-star rating, an increase from seven in 2025 but a significant decrease from 31 in 2024 and 57 in 2023. This context highlights the difficulty of achieving top ratings, suggesting Alignment's 4-star or greater rating for all members is a strong competitive achievement.
• We routinely take market share from large established players in highly competitive markets, a key source of our health plan membership growth in excess of the industry average. This suggests outperformance against competitors like United Health, Aetna, Humana, and Cigna, which are mentioned as having greater resources.
• As of January 1, 2026, we have approximately 275,300 Health Plan Members, which, according to CMS data, represent only 6% market share of Medicare Advantage enrollees in our markets. This indicates significant room for growth despite current market share, suggesting potential for continued expansion relative to the overall market.

Management Changes

Corporate Governance

Legal Proceedings

• **Dabney v. Alignment Healthcare USA, LLC**: A class action lawsuit filed April 27, 2022, alleging failure to provide hourly employees with required meal and rest breaks. A tentative settlement of $913,000 was accrued as of December 31, 2025, and the settlement was approved and paid in January 2026.
• **Maglione v. Alignment Healthcare, Inc., et al**: A class action lawsuit filed July 7, 2023, alleging certain provisions of the stockholder agreement with General Atlantic and Warburg Pincus violated Delaware law. The company agreed to amend the stockholder agreement on April 30, 2024, and the lawsuit was dismissed as moot on May 24, 2024. Settlement fees of $950,000 were agreed upon in March 2025 and paid in April 2025.
• **Risk Adjustment Data Validation (RADV) Audit**: On June 25, 2025, the company's California HMO plan was selected for a RADV audit for payment year 2019. CMS intends to apply a revised methodology (including extrapolation and no fee-for-service adjuster), but a federal district court vacated the 2023 final rule on procedural grounds on September 25, 2025, creating uncertainty regarding the audit methodology and potential payment recoveries. The company is currently collecting and reviewing medical records for the audit.

Related Party Transactions

• Joseph Konowiecki, Chairman of the Board, has a son who is a partner in McDermott Will & Emery LLP (MWE). MWE provided legal services to the company and its subsidiaries, receiving fees of approximately $429,000 in 2025, $272,000 in 2024, and $518,000 in 2023. Mr. Konowiecki's son does not receive direct compensation from these fees.

Stakeholder Impact

• **Shareholders**: The significant reduction in net loss and surge in Adjusted EBITDA are positive for shareholder value. However, potential dilution from convertible notes and future equity raises, along with stock price volatility, remain considerations. The CEO's PSU award aims to align management incentives with long-term shareholder interests.
• **Employees**: The company's human capital strategy focuses on attracting, developing, engaging, and retaining a diverse, high-performing workforce through competitive compensation, comprehensive benefits, positive work/life balance, and training programs. The hybrid-remote model enhances talent attraction. Competition for qualified personnel could increase labor costs.
• **Customers (Seniors/Members)**: The company's mission to improve healthcare for seniors, offering varied Medicare Advantage plans with enhanced benefits and high CMS Star Ratings, aims to provide easier access to care, better coordination, and improved health outcomes and satisfaction.
• **Providers**: The company works to empower community physicians by supplementing their care with additional clinical resources and sharing in upside through surplus gainsharing. However, risks exist regarding renegotiation, non-renewal, or termination of key contracts with IPAs, hospitals, and other provider networks.
• **CMS/Government**: As a government contractor, the company's operations are subject to extensive federal and state regulation, including CMS oversight, audits (like RADV), and potential changes to payment models (e.g., Inflation Reduction Act). Compliance with these regulations is critical to its business model and financial stability.

Next Steps

• Continue to invest heavily in increasing member base, growing provider networks, expanding operations geographically, and enhancing technology.
• Further develop the AVA platform and pursue new expansion opportunities.
• Create innovative product offerings and supplemental benefits to meet evolving senior consumer needs.
• CMS expects to begin issuing findings for payment year 2018 RADV audits in mid-2026 and plans to audit all eligible MA contracts annually going forward.
• Implement a cap on member out-of-pocket spending of $2,100 for Part D plans in 2026 as mandated by the Inflation Reduction Act.
• CMS will implement negotiated prices on certain high-cost Part D drugs in 2026.
• Comply with OCR's proposed HIPAA security standards rule, with final action scheduled for May 2026, potentially entailing significant additional compliance obligations and costs.
• Comply with CPPA's finalized regulations on risk assessments, cybersecurity assessments, and automated decision-making technologies (finalized September 23, 2025).
• Comply with new federal requirements for certain D-SNPs beginning in 2027, including integrated member ID cards and integrated health risk assessments.
• John Kao's PSU award has performance goals related to stock price hurdles ($33.75, $44.00, $55.25) over a five-year measurement period from January 24, 2026.
• Maintain compliance with financial covenants under the new revolving credit facility, starting with a Consolidated Senior Secured Leverage Ratio of not more than 2.50 to 1.00 and Consolidated EBITDA of at least $60,000,000 by June 30, 2026.

Key Dates

Recommendation

Alignment Healthcare demonstrates strong operational execution with significant revenue and membership growth, coupled with a substantial reduction in net loss and a dramatic increase in Adjusted EBITDA. The company's differentiated care model and high CMS Star Ratings are competitive advantages. However, the inherent regulatory risks of the Medicare Advantage market, including ongoing RADV audits and potential changes from the Inflation Reduction Act, along with the need for continued heavy investment in growth and technology, present notable uncertainties. While the financial trajectory is positive, a "Hold" recommendation is prudent given these persistent regulatory and operational challenges that could impact future profitability and stock price stability.

Keywords

Medicare Advantage, Healthcare, Health Plan, Seniors, Care Management, Technology Platform, AVA, CMS Star Ratings, Financial Performance, 10-K, Risk Adjustment, Convertible Notes, Revolving Credit Facility, Health Insurance, Population Health, Clinical Model, Data Analytics, Corporate Governance, Inflation Reduction Act